AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment.
Paris, February 3, 2026 – AndzonBio2, a biotechnology company focused on developing innovative therapeutic programs in neuroinflammation, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading experts in neuroscience,…
AndzonBio2 emerges from stealth mode and announces initial €3M seed fundingto advance breakthrough treatments for neurological disorders.
Paris, France, October 23, 2025 – AndzonBio2 emerges from stealth mode and announces a €3M ($3.5M) seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life…